A

    Akari Therapeutics PLC (AKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.43
    -0.27 (-2.52%)

    Market Cap: $20.83M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(15/23)
    Avg Surprise
    -38.48%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.04
    Range$-2.09 - $0.00
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.75+28.2%
    60d ago$-0.75+28.2%
    30d ago$-0.75+28.2%
    7d ago$-1.08-3.3%
    Current$-1.04
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.45
    Range$-5.79 - $4.88
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.45---
    Sep 26EST
    		-$-1.04---
    Jun 26
    Reported Aug 13
    		$-2.69$-1.04-158.47%Miss+31.4%
    Mar 26
    Reported Apr 7
    		$-9.72$-0.66-1372.91%Miss-5016.4%
    Dec 25
    Reported Dec 31
    		$N/A$-2.40N/ABeat-
    Sep 25
    Reported Nov 13
    		$-1.06N/A+75.91%Beat-32.1%
    Jun 25
    Reported Aug 13
    		$-3.92$-4.80+18.33%Beat-373.7%
    Mar 25
    Reported Apr 14
    		$-0.19N/A+81.00%Beat+92.1%
    Sep 24
    Reported Nov 18
    		$-9.59N/AN/ABeat-
    Jun 24
    Reported Aug 18
    		$-0.80$0.00N/ABeat-
    Mar 24
    Reported May 14
    		$-0.83$0.00N/ABeat-934.4%
    Dec 23
    Reported Mar 29
    		$-2.40$0.00N/ABeat-2900.0%
    Sep 23
    Reported Oct 3
    		$0.00N/A+100.00%Beat+100.0%
    Jun 23
    Reported Jul 19
    		$0.00N/A+100.00%Beat+100.0%
    Mar 23
    Reported May 1
    		$-0.08$-0.07-14.29%Miss+34.2%
    Dec 22
    Reported Mar 9
    		$-0.08$-0.07-14.29%Miss-156.4%
    Sep 22
    Reported Dec 30
    		$-0.04$-0.04+0.00%Beat+73.6%
    Jun 22
    Reported Sep 27
    		$-0.10N/AN/ABeat-866.0%
    Mar 22
    Reported May 16
    		$-0.12N/AN/ABeat-380.8%
    Sep 21
    Reported Dec 3
    		$-0.03$0.00N/ABeat+98.4%
    Jun 21
    Reported Sep 22
    		$-0.15$0.00N/ABeat-16.8%
    Mar 21
    Reported Apr 20
    		$-0.01N/AN/ABeat+97.4%
    Sep 20
    Reported Dec 11
    		$0.04$0.00N/ABeat+130.9%
    Jun 20
    Reported Sep 1
    		$-2.00$0.00N/ABeat-700.0%
    Mar 20
    Reported May 29
    		$-0.13$0.00N/ABeat+13.3%
    Dec 19
    Reported Mar 31
    		$-0.39$-0.14-178.57%Miss-75.5%
    Sep 19
    Reported Nov 4
    		$-0.14$-0.12-16.67%Miss+40.5%
    Jun 19
    Reported Aug 29
    		$-0.25$-0.13-92.31%Miss+52.8%
    Mar 19
    Reported Apr 23
    		$-0.15N/A+99.63%Beat+74.1%
    Dec 18
    Reported Mar 18
    		$-0.22$0.00N/AMiss+97.2%
    Sep 18
    Reported Nov 15
    		$-0.24N/A+97.06%Beat+97.1%
    Jun 18
    Reported Aug 17
    		$-0.53N/A+93.38%Beat-1827.3%
    Mar 18
    Reported May 30
    		$-0.58$-0.72+19.44%Beat+92.8%
    Dec 17
    Reported Mar 21
    		$-8.00$-8.00+0.00%Beat-700.0%
    Sep 17
    Reported Nov 13
    		$-8.00$-8.00+0.00%Beat-22435.2%
    Jun 17
    Reported Aug 10
    		$-0.03N/A+100.00%Beat-
    Mar 17
    Reported May 15
    		$-8.00N/A+98.15%Beat-
    Dec 16
    Reported Mar 31
    		$-1.00$-0.83-20.48%Miss-
    Sep 16
    Reported Nov 10
    		$-0.04N/A+99.99%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.60EV/EBITDA-0.06x
    Price/FCF-1.74xFCF Yield-57.48%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-140.10%ROIC-89.78%
    Financial Health
    Debt/Equity0.04xInterest Coverage-19.35x
    Current Ratio0.60xQuick Ratio0.60x
    Trading Statistics
    Beta1.39Avg Volume64.49K
    52-Week High$49.6052-Week Low$3.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.60
    SMA 20$8.04
    SMA 50$9.61
    SMA 200$10.11
    EMA 10$8.95
    EMA 20$8.66
    EMA 50$9.17
    EMA 200$13.51

    MACD

    Line: 0.07Signal: -0.39Hist: 0.47

    ADX

    ADX: 22.0+DI: 27.6-DI: 10.8

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down56.0
    PSAR$7.22

    Bollinger Bands

    Upper Band$10.07
    Lower Band$6.02
    %B Position5035%(Upper)
    Band Width1.09

    RSI (14-Day)

    Neutral
    62.4

    Momentum Oscillators

    Stoch %K81.4
    Stoch %D79.6
    Williams %R-19.8
    ROC (10d)38.7%
    Momentum2.91
    CCI (20d)247.7
    MFI (14d)89.3

    Volatility Measures

    ATR (14d)$1.13(10.8%)
    StdDev (20d)1.01
    Hist Vol119.1%(High)

    Volume Flow

    VWAP$10.53
    OBV16.7M
    AD Line803554904079.4B
    CMF (20d)0.077

    Volume Metrics

    Avg Vol (20d)66.5K
    Vol Ratio1.2x
    VWMA (20d)$8.47

    Pivot Points

    R3$13.87
    R2$12.47
    R1$11.59
    Pivot Point$10.19
    S1$9.31
    S2$7.91
    S3$7.03

    Advanced Oscillators

    TSI1.43
    Ultimate Osc53.3
    KST-76.80

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$25,998$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/A$1,000N/AN/AN/A$12,999N/AN/A
    Gross ProfitN/AN/AN/AN/AN/A$-1,000N/AN/AN/A$-12,999N/AN/A
    Operating Expenses$4.60M$15.76M$3.23M$7.40M$3.12M$3.52M$4.29M$2.93M$7.45M$5.98M$5.09M$2.51M
    R&D$2.08M$1.46M$1.09M$249,000$667,000$813,000$1.25M$143,000$3.31M$2.28M$5.08M$314,000
    SG&A$2.52M$2.17M$2.14M$1.98M$2.45M$2.71M$3.05M$1.71M$2.24M$3,710$2.58M$2.82M
    Operating Income$-4,602,000$-15,758,000$-3,227,000$-7,404,000$-3,119,000$-3,525,000$-4,295,000$-2,927,000$-7,449,000$-5,989,000$-5,090,000$-2,507,000
    Interest Income$0$0$0$1,000$0$0$1,000$3,000$2,000$2$7,000$16,000
    Interest Expense$80,000$61,000$723,000$120,273$50,000$55,000$124,000$69,000$51,000$0$0$0
    Income Before Tax$-4,807,000$-15,314,000$-5,213,000$-7,488,000$-1,895,000$-3,705,000$-3,772,000$-2,895,000$-7,558,000$-5,566,000$-4,138,000$-2,871,000
    Income Tax Expense$0$-859,000$85,000$-1,088,000$0$0$0$0$0$1$0$0
    Net Income$-4,807,000$-14,455,000$-5,298,000$-6,400,000$-1,895,000$-3,705,000$-3,772,000$-2,895,000$-7,558,000$-5,566,000$-4,138,000$-2,871,000
    EBITDA$-4,477,000$-15,253,000$-4,490,000$-7,367,000$-1,845,000$-3,650,000N/A$-2,826,000$-7,507,000$-5,553,001$-4,137,000$-2,870,000
    EBITN/AN/AN/AN/A$-3,119,000$-3,648,000$-4,295,000$-2,949,001$-7,449,000$-5,566,000$-4,138,000$-2,871,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AKTX

    News

    Akari Therapeutics (NASDAQ: AKTX) insider updates holdings

    Akari Therapeutics' Interim CFO, Farag Kameel D., reported an acquisition of 1,728 American Depositary Shares (ADS) valued at $7.52 each, totaling approximately $13,000. These shares represent restricted stock units set to vest fully on September 15, 2026. Following this transaction, Farag Kameel D. directly holds 23,309 ADSs in the company.

    Stock Titan•8/19/26•
    Neutral

    Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

    Akari Therapeutics announced new preclinical data for AKTX-101, its TROP2-targeted antibody-drug conjugate (ADC), showing robust anti-tumor activity in urothelial cancer models. The data supports the potential of its novel PH1 RNA spliceosome-modulating payload to overcome resistance to existing ADCs. Akari plans to advance AKTX-101 towards Phase 1 clinical development by mid-2027.

    Sahm•8/19/26•
    Bullish

    Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

    Akari Therapeutics (NASDAQ: AKTX) announced promising preclinical results for its experimental cancer treatment, AKTX-101, a TROP2-directed ADC designed to address the shortcomings of existing antibody-drug conjugates in urothelial cancer. The therapy showed significant tumor growth inhibition in models where standard treatments like Padcev were less effective, and even against tumors resistant to Trodelvy. Akari aims to initiate a Phase 1 clinical trial for AKTX-101 by mid-2027, while exploring further development opportunities for its PH1 payload platform.

    Benzinga•8/18/26•
    Bullish

    Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

    Akari Therapeutics announced new preclinical data for its TROP2-targeted antibody drug conjugate (ADC) AKTX-101, showing robust anti-tumor activity in urothelial cancer models. The data supports the potential of Akari's novel PH1 RNA spliceosome-modulating payload to overcome resistance seen with existing ADC therapies. Akari plans to advance AKTX-101 towards Phase 1 clinical development in mid-2027, highlighting its differentiated approach to address unmet needs in oncology, particularly for patients who relapse after conventional ADC treatments.

    The Manila Times•8/18/26•
    Bullish

    Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

    Akari Therapeutics announced new preclinical data for AKTX-101, its TROP2-targeted Antibody Drug Conjugate (ADC), demonstrating significant anti-tumor activity in urothelial cancer models. The data supports the potential of its novel PH1 RNA spliceosome-modulating payload to overcome resistance associated with current ADC therapies and to provide a differentiated treatment strategy. Akari plans to advance AKTX-101 into Phase 1 clinical development by mid-2027.

    GlobeNewswire•8/18/26•
    Bullish

    Frequently Asked Questions About AKTX

    Does AKTX pay dividends?
    Akari Therapeutics PLC (AKTX) does not currently pay a regular dividend.
    What is AKTX's market cap?
    Akari Therapeutics PLC (AKTX) has a market capitalization of $20.83M with a current stock price of $10.43.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In